G1 Therapeutics P/E Ratio

G1 Therapeutics (GTHX) currently reports a P/E ratio of -7.7. That is below the Healthcare sector average of 22.57. Use the charts on this page to explore G1 Therapeutics's P/E ratio history and peer comparisons.

G1 Therapeutics's P/E ratio of -7.7 is lower than the Healthcare sector average of 22.57. That is roughly 134.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates G1 Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -7.7, GTHX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -7.7, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.57. From there, open related valuation or income-statement pages for G1 Therapeutics, and consider following GTHX for alerts when major investors trade the stock.

G1 Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -7.7 versus a sector average near 22.57. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GTHX with unrelated industries.